Company / R&D Expense
Phio Pharmaceuticals Corp. R&D Expense History
FY2012-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$4.3M
FY2020
5-year range
$4.3M / $6.9M
FY2016-FY2020
Trend
-0.6%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 5 consecutive years, from $10M in FY2013 to $4M in FY2020.
Based on SEC 10-K filings.
$4M in FY2020 with a 3-year CAGR of -7.4%.
Declined from $5M to $4M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -7.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Phio Pharmaceuticals Corp.'s r&d expense has declined for 5 consecutive years.
- 3-year CAGR of -7.4%, indicating a declining trend.
- In FY2020, r&d expense decreased 0.6% year-over-year.
- Peak r&d expense was recorded in FY2013.
Company context
Key Data Points
- Altman Z-Score -0.94 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $4.3M | -0.6% |
| FY2019 | $4.3M | -19.4% |
| FY2018 | $5.4M | -0.8% |
| FY2017 | $5.4M | -21.8% |
| FY2016 | $6.9M | -33.7% |
| FY2013 | $10.5M | +57.8% |
| FY2012 | $6.6M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026